

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person Aklog Lishan		2. Issuer Name and Ticker or Trading Symbol PAVmed Inc. [PAVM]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chairman and CEO	
(Last) (First) (Middle) ONE GRAND CENTRAL PLACE, SUITE 4600		3. Date of Earliest Transaction (Month/Day/Year) 08/29/2017			
(Street) NEW YORK, NY 10165		4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/29/2017		P		1,412	A	(1)	60,289	D	
Common Stock	08/30/2017		P		300	A	(2)	60,589	D	
Common Stock	08/31/2017		P		1,600	A	(3)	62,189	D	
Common Stock	09/01/2017		P		300	A	(4)	62,489	D	
Common Stock								285	I	By daughter
Common Stock								300	I	By son
Common Stock								5,713,879	I	By HCFP/Capital Partners III LLC (8)
Common Stock								2,520,532	I	By Pavilion Venture Partners LLC (9)
Common Stock								87,020	I	By HCFP Inc. (10)
Common Stock								125,000	I	By HCFP/Capital Partners IIIB LLC (11)
Common Stock								20,000	I	By HCFP/AG LLC (12)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrants	\$ 5	08/29/2017		P		1,200		10/28/2016	01/29/2022	Common Stock	1,200	(5)	46,500	D	
Warrants	\$ 5	08/30/2017		P		200		10/28/2016	01/29/2022	Common Stock	200	\$ 1.22	46,700	D	
Warrants	\$ 5	08/31/2017		P		1,700		10/28/2016	01/29/2022	Common Stock	1,700	(6)	48,400	D	

Warrants	\$ 5	09/01/2017		P	200	10/28/2016	01/29/2022	Common Stock	200	(7)	48,600	D	
Warrants	\$ 5					10/28/2016	01/29/2022	Common Stock	5,713,879		5,713,879	I	By HCFP/Capital Partners III LLC (8)
Warrants	\$ 5					10/28/2016	01/29/2022	Common Stock	2,220,532		2,220,532	I	By Pavilion Venture Partners LLC (9)
Warrants	\$ 5					10/28/2016	01/29/2022	Common Stock	387,020		387,020	I	By HCFP Inc. (10)
Warrants	\$ 5					10/28/2016	01/29/2022	Common Stock	125,000		125,000	I	By HCFP/Capital Partners IIIB LLC (11)
Warrants	\$ 5					10/28/2016	01/29/2022	Common Stock	20,000		2,000	I	By HCFP/AG LLC (12)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Aklog Lishan ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165	X	X	Chairman and CEO	
HCFP/Capital Partners III LLC ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165		X		
Pavilion Venture Partners LLC ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165		X		

Signatures

/s/ Dr. Lishan Aklog		09/05/2017
<small>Signature of Reporting Person</small>		<small>Date</small>
/s/ Dr. Lishan Aklog, as manager of HCFP/Capital Partners III LLC		09/05/2017
<small>Signature of Reporting Person</small>		<small>Date</small>
/s/ Dr. Lishan Aklog, as manager of Pavilion Venture Partners LLC		09/05/2017
<small>Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares were purchased at a weighted average price of approximately \$4.19770538 per share. These shares were purchased in multiple transactions at prices ranging from \$4.18 to \$4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

The shares were purchased at a weighted average price of approximately \$4.19666667 per share. These shares were purchased in multiple transactions at prices ranging from \$4.19 to \$4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

The shares were purchased at a weighted average price of approximately \$4.2725 per share. These shares were purchased in multiple transactions at prices ranging from \$4.20 to \$4.40, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

The shares were purchased at a weighted average price of approximately \$4.45666667 per share. These shares were purchased in multiple transactions at prices ranging from \$4.39 to \$4.50, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

The warrants were purchased at a weighted average price of approximately \$1.4875 per warrant. These warrants were purchased in multiple transactions at prices ranging from \$1.18 to \$2.24, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth in this footnote to this Form 4.

The warrants were purchased at a weighted average price of approximately \$1.0375 per warrant. These warrants were purchased in multiple transactions at prices ranging from \$1.01 to \$1.09, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth in this footnote to this Form 4.

- The warrants were purchased at a weighted average price of approximately \$1.19 per warrant. These warrants were purchased in multiple transactions at prices ranging from \$1.18 to \$1.20, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth in this footnote to this Form 4.
- (7) Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
 - (8) Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
 - (9) Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
 - (10) Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
 - (11) Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
 - (12)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.